Mirati’s Adagrasib Takes The Lead Among KRAS G12C Inhibitors In CRC

Monotherapy, Combo Data Outshine Amgen’s Lumakras

 
• By Mandy Jackson
  
Yellow paper boat breaks out of order from other paper boats
Mirati's adagrasib may pull out from behind Amgen's Lumakras lead in lung cancer with an accelerated approval in colorectal cancer • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D